Diagnostic Approach for Tuberculosis When Sputum Production and Biopsy Are Not Feasible

Primary Diagnostic Strategy

The American Thoracic Society recommends sputum induction with hypertonic saline as the first-line approach when patients cannot spontaneously produce sputum, and should be performed under appropriate infection control measures 1, 3
At minimum, three induced sputum specimens should be obtained for acid-fast bacilli (AFB) smears and mycobacterial cultures, as recommended by the American Thoracic Society 3
The Centers for Disease Control and Prevention (CDC) suggests that post-bronchoscopy sputum specimens may yield positive results even when bronchoalveolar lavage (BAL) specimens are negative 2
The American College of Chest Physicians recommends bronchoscopy with bronchoalveolar lavage when induced sputum is unsuccessful or non-diagnostic, with a strength of evidence rated as high 1, 3
For cavitary lesions, the Infectious Diseases Society of America recommends bronchial washings or lavage can provide diagnostic material, with a moderate level of evidence 1
A single positive bronchoscopic specimen for M. tuberculosis in patients with classic symptoms and radiographic findings consistent with TB is considered adequate for diagnosis, according to the American Thoracic Society, with a high strength of evidence 4

The CDC recommends nucleic acid amplification testing (NAAT) on respiratory specimens provides rapid identification of M. tuberculosis and should be performed on available specimens, with a high strength of evidence 2
The American Academy of Pediatrics suggests tuberculin skin test (TST) or interferon-gamma release assay (IGRA) should be performed; a positive result (≥5mm for TST) supports the diagnosis of culture-negative pulmonary tuberculosis, with a moderate level of evidence 2

The World Health Organization (WHO) recommends that for patients with high clinical suspicion based on radiographic findings (especially cavitary lesions) and symptoms, empiric treatment with isoniazid (INH), rifampin (RIF), pyrazinamide (PZA), and ethambutol (EMB) should be initiated even when initial smears are negative, with a high strength of evidence 3, 2
The WHO also recommends a thorough clinical and radiographic evaluation should be performed at 2 months of therapy to determine whether there has been a response attributable to antituberculosis treatment, with a moderate level of evidence 5, 3, 2

The European Respiratory Society recommends that alternative diagnoses must be considered carefully before making a presumptive diagnosis of culture-negative tuberculosis, with a high strength of evidence 5, 3
The Infectious Diseases Society of America suggests nontuberculous mycobacteria (NTM) can present with cavitary lung disease and must be excluded through species identification if cultures become positive, with a moderate level of evidence 6, 7
The American College of Chest Physicians recommends that culture remains essential for definitive diagnosis as it distinguishes between viable and non-viable organisms and allows for drug susceptibility testing, with a high strength of evidence 8

The WHO recommends never initiate single-drug therapy or add a single drug to a failing regimen, as this leads to development of drug resistance, with a high strength of evidence 2
The CDC suggests the four-drug initial regimen (INH, RIF, PZA, EMB) is recommended even with negative smears because of the possibility of drug resistance, with a moderate level of evidence 5, 3
The American Thoracic Society recommends susceptibility testing for INH, RIF, and EMB should be performed on any positive culture, regardless of specimen source, with a high strength of evidence 1